Foghorn Therapeutics (FHTX) outlined its objectives for 2025 on Monday, including advancing its inhibitor and degrader program trials.
The company said it will continue to enroll and dose patients in a phase 1 trial of FHD-909 to treat solid tumors. It will also present preclinical combination data for FHD-909 with pembrolizumab and KRAS inhibitors at the American Association for Cancer Research's annual meeting in April, the company said.
"We are continuing to advance our Selective CBP degrader and our Selective EP300 degrader, which are both implicated in a wide range of cancers," Chief Executive Adrian Gottschalk said in a statement.
Foghorn said that as of the end of 2024, it had $243.8 million cash, cash equivalents and marketable securities that will provide a cash runway into 2027.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。